Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

Rituximab (RTX), a chimeric IgG1 monoclonal antibody directed against the CD20 antigen, has revolutionized the treatment of B-cell malignancies. Nevertheless, the relapsed/refractory rates are still high. One strategy to increase the clinical effectiveness of RTX is based on antibody-cytokine fusion...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Vincent, Marie, Teppaz, Géraldine, Lajoie, Laurie, Solé, Véronique, Bessard, Anne, Maillasson, Mike, Loisel, Séverine, Béchard, David, Clémenceau, Béatrice, Thibault, Gilles, Garrigue-Antar, Laure, Jacques, Yannick, Quéméner, Agnès
Format: Artigo
Jezik:Inglês
Izdano: Landes Bioscience 2014
Teme:
Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4171006/
https://ncbi.nlm.nih.gov/pubmed/25072059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.28699
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items